Fig. 3

PLD2 inhibition accelerates SAHA-induced suppression of cancer cell proliferation. a MDA-MB231 cells were treated with the indicated dose of SAHA for 36 h and cell viability was measured using MTT assay. b MDA-MB-231 cells were transfected with siRNA of PLD2 for 24 h and treated with or without SAHA (5 μM) for 36 h. Relative cell viability was examined by MTT assay. c MDA-MB-231 cells were treated with SAHA (5 μM) and/or PLD2 inhibitor (10 μM) for 1 h. PLD activity was measured as described in “Materials and methods”. d MDA-MB-231 cells were treated with SAHA and/or PLD2 inhibitor for 36 h. The percentage of S-phase cells was determined on the basis of BrdU incorporation in the cells as measured by flow cytometry. e MCF10A and MDA-MB231 cells were treated with SAHA (5 μM) and PLD2 inhibitor (10 μM) for 36 h and cell viability was measured using MTT assay. Results are representative of at least four independent experiments and shown as the mean ± SEM. *p < 0.01; **p < 0.001